Jefferies Group set a $76.00 target price on CVS Health (NYSE:CVS) in a research note published on Monday morning. The firm currently has a hold rating on the pharmacy operator’s stock.

CVS has been the topic of a number of other research reports. Loop Capital reduced their target price on CVS Health from $83.00 to $73.00 and set a hold rating on the stock in a report on Tuesday, November 7th. Needham & Company LLC raised their target price on CVS Health from $79.00 to $85.00 and gave the stock a buy rating in a report on Monday. Deutsche Bank assumed coverage on CVS Health in a report on Monday. They set a buy rating and a $90.00 target price on the stock. Oppenheimer restated a buy rating and set a $95.00 target price on shares of CVS Health in a report on Monday, October 9th. Finally, TheStreet cut CVS Health from a b- rating to a c+ rating in a report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $86.35.

Shares of CVS Health (CVS) traded up $1.86 during mid-day trading on Monday, reaching $72.95. The company had a trading volume of 3,551,753 shares, compared to its average volume of 6,927,214. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. The firm has a market capitalization of $72,307.37, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 1.34 and a beta of 0.89. CVS Health has a 1 year low of $66.45 and a 1 year high of $84.72.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The firm had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The company’s revenue was up 3.5% on a year-over-year basis. During the same period last year, the company earned $1.64 earnings per share. analysts expect that CVS Health will post 5.9 EPS for the current year.

In other CVS Health news, EVP Thomas M. Moriarty sold 20,547 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total value of $1,667,799.99. Following the sale, the executive vice president now owns 43,178 shares in the company, valued at approximately $3,504,758.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Thomas M. Moriarty sold 90,267 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.61, for a total value of $7,186,155.87. Following the completion of the sale, the executive vice president now owns 70,102 shares in the company, valued at approximately $5,580,820.22. The disclosure for this sale can be found here. Insiders sold a total of 714,125 shares of company stock worth $58,119,381 in the last 90 days. Company insiders own 0.61% of the company’s stock.

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of CVS Health by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 76,557,597 shares of the pharmacy operator’s stock worth $6,159,825,000 after acquiring an additional 1,056,265 shares during the last quarter. FMR LLC increased its holdings in shares of CVS Health by 22.0% during the 2nd quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock worth $2,425,920,000 after acquiring an additional 5,446,930 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of CVS Health by 1.8% during the 1st quarter. Bank of America Corp DE now owns 22,411,957 shares of the pharmacy operator’s stock worth $1,759,338,000 after acquiring an additional 398,999 shares during the last quarter. Northern Trust Corp increased its holdings in shares of CVS Health by 5.5% during the 2nd quarter. Northern Trust Corp now owns 15,618,081 shares of the pharmacy operator’s stock worth $1,256,631,000 after acquiring an additional 807,639 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of CVS Health by 8.4% during the 2nd quarter. Nordea Investment Management AB now owns 14,154,922 shares of the pharmacy operator’s stock worth $1,138,905,000 after acquiring an additional 1,100,373 shares during the last quarter. 82.24% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “CVS Health (CVS) Given a $76.00 Price Target by Jefferies Group Analysts” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/08/cvs-health-cvs-given-a-76-00-price-target-by-jefferies-group-analysts.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.